# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)

> **NCT02059174** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 76 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** MK-1293
- **DRUG:** EU-Lantus™
- **DRUG:** Novolog™

## Key facts

- **NCT ID:** NCT02059174
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-10
- **Primary completion:** 2015-03-30
- **Final completion:** 2015-04-27
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2018-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02059174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02059174, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02059174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*